Literature DB >> 17293231

Determining optimal clinical target volume margins on the basis of microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer.

Shuanghu Yuan1, Xue Meng, Jinming Yu, Dianbin Mu, K S Clifford Chao, Jiandong Zhang, Weixia Zhong, Yonghua Yu, Jialin Wang, Xindong Sun, Guoren Yang, Yongzheng Wang.   

Abstract

PURPOSE: To determine the optimal clinical target volume (CTV) margins around the nodal gross tumor volume (GTV) in non-small-cell lung cancer (NSCLC) patients by assessing microscopic tumor extension beyond regional lymph node capsules. METHODS AND MATERIALS: The incidence of nodal extracapsular extension (ECE) and relationship with nodal size were reviewed in 243 patients. Histologic sections of dissected regional lymph nodes up to 30 mm in size were examined to measure the extent of microscopic ECE. We determined the distribution of cases according to extent of ECE and the relationships between ECE extent and lymph node size, regional nodal disease extent, histologic type, and degree of differentiation.
RESULTS: The nodal ECE was seen in 41.6% of patients (101/243) and 33.4% of lymph nodes (214/640), and the incidence correlated to larger lymph node size positively. The extent of ECE was 0.7 mm in mean (range, 0-12.0 mm) and <or=3 mm in 95% of the nodes. Positive correlations were found between extent of ECE and larger lymph node size (>or=20 mm vs. 10-19 mm or <10 mm, p = 0.005), advanced nodal stage (N2 vs. N1, p = 0.046), and moderate or poor (vs. good or unknown) nodal differentiation (p = 0.002). ECE did not differ significantly by histologic type or nodal station.
CONCLUSIONS: The incidence of ECE related to lymph node size, and ECE extent related to lymph node size, stage, and differentiation. It may be reasonable to recommend 3-mm CTV margins for pathologic lymph nodes <20 mm and more generous margins for lymph nodes >or=20 mm.

Entities:  

Mesh:

Year:  2007        PMID: 17293231     DOI: 10.1016/j.ijrobp.2006.08.057

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.

Authors:  Aparna H Kesarwala; Christine J Ko; Holly Ning; Eric Xanthopoulos; Karl E Haglund; William P O'Meara; Charles B Simone; Ramesh Rengan
Journal:  Clin Lung Cancer       Date:  2014-12-09       Impact factor: 4.785

2.  Is a clinical target volume (CTV) necessary for locally advanced non-small cell lung cancer treated with intensity-modulated radiotherapy? -a dosimetric evaluation of three different treatment plans.

Authors:  Fan Xia; Lijun Zhou; Xi Yang; Li Chu; Xiaofei Zhang; Jinjin Chu; Weigang Hu; Zhengfei Zhu
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy.

Authors:  Weihu Wang; Xiaoli Feng; Tao Zhang; Jing Jin; Shulian Wang; Yueping Liu; Yongwen Song; Xinfan Liu; Zihao Yu; Yexiong Li
Journal:  Radiat Oncol       Date:  2010-08-23       Impact factor: 3.481

4.  Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer.

Authors:  Xuquan Jing; Xue Meng; Xindong Sun; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-02-19       Impact factor: 4.147

5.  Evaluation of Microscopic Tumour Extension in Localized Stage Non-Small-Cell Lung Cancer for Stereotactic Radiotherapy Planning.

Authors:  Martin Schmitt; Lucie Aussenac; Joseph Seitlinger; Véronique Lindner; Georges Noël; Delphine Antoni
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

6.  Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer.

Authors:  Vittorio Donato; Stefano Arcangeli; Alessia Monaco; Cristina Caruso; Michele Cianciulli; Genoveva Boboc; Cinzia Chiostrini; Roberta Rauco; Maria Cristina Pressello
Journal:  Front Oncol       Date:  2013-11-18       Impact factor: 6.244

7.  Dosimetric Analysis of Microscopic Disease in SBRT for Lung Cancers.

Authors:  Ronghu Mao; Lingling Tian; You Zhang; Lei Ren; Renqi Gao; Fang-Fang Yin; Hong Ge
Journal:  Technol Cancer Res Treat       Date:  2017-10-11

Review 8.  Stereotactic Radiotherapy for Oligometastases in Lymph Nodes-A Review.

Authors:  Haruo Matsushita; Keiichi Jingu; Rei Umezawa; Takaya Yamamoto; Yojiro Ishikawa; Noriyoshi Takahashi; Yu Katagiri; Noriyuki Kadoya
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.